Literature DB >> 923614

Tumour regression and survival of patients with disseminated malignant melanoma treated with chemotherapy and specific active immunotherapy.

D W Hedley, T J McElwain, G A Currie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 923614     DOI： 10.1016/0014-2964(77)90017-2

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0014-2964            Impact factor:   9.162


× No keyword cloud information.
  4 in total

Review 1.  Chemotherapy of malignant melanoma.

Authors:  R S Benjamin
Journal:  World J Surg       Date:  1979-07-30       Impact factor: 3.352

Review 2.  Combined modality therapy of malignant melanoma.

Authors:  E M Hersh; J U Gutterman; C M McBride
Journal:  World J Surg       Date:  1979-07-30       Impact factor: 3.352

Review 3.  Cancer immunotherapy.

Authors:  S P Richman; J U Gutterman; E M Hersh
Journal:  Can Med Assoc J       Date:  1979-02-03       Impact factor: 8.262

4.  Specific active immunotherapy does not prolong survival in surgically treated patients with stage IIB malignant melanoma and may promote early recurrence.

Authors:  D W Hedley; T J McElwain; G A Currie
Journal:  Br J Cancer       Date:  1978-04       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.